Patents by Inventor Trevor John Lockett
Trevor John Lockett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190024188Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as a adenoma or an adeocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinoma.Type: ApplicationFiled: October 2, 2018Publication date: January 24, 2019Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence C. LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON, Peter Laurence MOLLOY
-
Publication number: 20180100200Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: November 10, 2017Publication date: April 12, 2018Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON
-
Publication number: 20170211152Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: December 16, 2016Publication date: July 27, 2017Inventors: Lawrence Charles LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON
-
Publication number: 20150159223Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: November 13, 2014Publication date: June 11, 2015Inventors: Lawrence Charles LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON
-
Publication number: 20140287940Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas.Type: ApplicationFiled: October 18, 2013Publication date: September 25, 2014Applicants: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence C. LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON, Peter Laurence MOLLOY
-
Publication number: 20110098189Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas.Type: ApplicationFiled: October 23, 2008Publication date: April 28, 2011Applicants: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence C. Lapointe, Robert Dunne, Graeme P. Young, Trevor John Lockett, William J. Wilson, Peter Laurence Molloy
-
Publication number: 20100292094Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: October 23, 2008Publication date: November 18, 2010Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles Lapointe, Robert Dunne, Graeme P. Young, Trevor John Lockett, William J. Wilson
-
Patent number: 6828148Abstract: This invention is directed to a class of miniribozymes, capable of hybridizing with a target RNA to be cleaved and exhibiting very high cleavage rates at low Mg2+ concentration. The miniribozymes may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.Type: GrantFiled: June 22, 2001Date of Patent: December 7, 2004Assignee: Gene Shears Pty. LimitedInventors: Jason Francis Conaty, Philip Hendry, Trevor John Lockett
-
Publication number: 20020155454Abstract: This invention is directed to a class of miniribozymes, capable of hybridizing with a target RNA to be cleaved and exhibiting very high cleavage rates at low Mg2+ concentration. The miniribozymes may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.Type: ApplicationFiled: June 22, 2001Publication date: October 24, 2002Inventors: Jason Francis Conaty, Philip Hendry, Trevor John Lockett
-
Patent number: 5854224Abstract: The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having the formula ##STR1## in which: w is a nucleic acidx is a non-amino acid or non-peptide nucleic acid binding groupy is a spacer having a chain length equivalent to 1-30 carbon-carbon single covalent bonds or is absentR.sub.4 is H or halogen or CH.sub.2 O--R.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are the same or different and are either hydrogen, methyl, ethyl, alkyl, alkenyl, hydroxylated alkyl, hydroxylated alkenyl groups or ether containing alkyl, alkenyl, hydroxylated alkyl or hydroxylated alkenyl groups optionally being an acyl group having a carbon chain length equivalent to 3-24 carbon atoms saturated or unsaturated, with the proviso that at least one of R.sub.1, R.sub.2 or R.sub.3 includes a group having a carbon chain of 3-24 carbon atoms saturated or unsaturated, or to a compound having the formula:w . . . y--y--NH--CH.sub.2 --CH.sub.2 O--R.sub.Type: GrantFiled: September 25, 1996Date of Patent: December 29, 1998Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Trevor John Lockett, Robert George Whittaker, Fiona Helen Cameron, Minoo Jalili Moghaddam, Simon MacEwan Carroll